Filtered By:
Vaccination: Influenza Vaccine

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 1458 results found since Jan 2013.

Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru
The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines with more antigens remain apparent in parts of these countries, where vaccine-preventable diseases in infants continue to be a major problem. The challenges include the heterogeneity of vaccine coverage within each country and in neighboring countries, which can contribute to poor rates of vaccination coverage; the adverse impact of the inward migration of unvaccinated individuals, which has favored the re-emergence of...
Source: Pan American Journal of Public Health - February 2, 2023 Category: International Medicine & Public Health Authors: Carlos Torres-Martinez Eduardo Chaparro Ana-Cristina Mari ño Luiza Helena Falleiros-Arlant Germ án Camacho-Moreno Mar ía E Castillo Carlos Garces Wilfrido Coronell Roberto Somocurcio Source Type: research

Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Mol Biotechnol. 2023 Jan 31. doi: 10.1007/s12033-023-00679-1. Online ahead of print.ABSTRACTNovel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were investigated in several viral infectio...
Source: Herpes - January 31, 2023 Category: Infectious Diseases Authors: Niloofar Khairkhah Ali Namvar Azam Bolhassani Source Type: research

Physical interventions to interrupt or reduce the spread of respiratory viruses
CONCLUSIONS: The high risk of bias in the trials, variation in outcome measurement, and relatively low adherence with the interventions during the studies hampers drawing firm conclusions. There were additional RCTs during the pandemic related to physical interventions but a relative paucity given the importance of the question of masking and its relative effectiveness and the concomitant measures of mask adherence which would be highly relevant to the measurement of effectiveness, especially in the elderly and in young children. There is uncertainty about the effects of face masks. The low to moderate certainty of evidenc...
Source: Cochrane Database of Systematic Reviews - January 30, 2023 Category: General Medicine Authors: Tom Jefferson Liz Dooley Eliana Ferroni Lubna A Al-Ansary Mieke L van Driel Ghada A Bawazeer Mark A Jones Tammy C Hoffmann Justin Clark Elaine M Beller Paul P Glasziou John M Conly Source Type: research

Viruses, Vol. 15, Pages 392: Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?
uan With technological advancements enabling globalization, the intercontinental transmission of pathogens has become much easier. Respiratory viruses are one such group of pathogens that require constant monitoring since their outbreak leads to massive public health crises, as exemplified by the influenza virus, respiratory syncytial virus (RSV), and the recent coronavirus disease 2019 (COVID-19) outbreak caused by the SARS-CoV-2. To prevent the transmission of these highly contagious viruses, developing prophylactic tools, such as vaccines, is of considerable interest to the scientific community. Virus-like particles...
Source: Viruses - January 30, 2023 Category: Virology Authors: Ki-Back Chu Fu-Shi Quan Tags: Review Source Type: research

FDA Experts Vote to Make All COVID-19 Vaccines and Boosters Bivalent
In a unanimous decision, all 21 voting members of the U.S. Food and Drug Administration’s (FDA) vaccine committee recommended that the U.S. start using the same COVID-19 virus strain in all of the COVID-19 vaccines, including primary and booster doses. That means the bivalent booster dose, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/5 strains, would soon become the only type used for all primary shots and boosters. The decision reflects a turning point in the pandemic. Until now, vaccine makers have tried to keep up with constantly evolving variants, but they’ve always been a few step...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Protein decoys for viruses may battle COVID-19 and more
As the fight against COVID-19 wears on and the virus continues to mutate, vaccines and several monoclonal antibody drugs are losing some of their punch. That’s added urgency to a strategy for preventing and treating the disease that, in theory, could stop all variants of SARS-CoV-2. The idea is to flood the body with proteins that mimic the angiotensin-converting enzyme 2 (ACE2) receptor, the cell-surface protein that SARS-CoV-2 uses to gain entry into cells. These decoys would bind to the virus’ spike protein, disarming it. The molecules might both protect people from getting infected and help COVID-19 patients clear ...
Source: Science of Aging Knowledge Environment - January 26, 2023 Category: Geriatrics Source Type: research

What ’s next for COVID-19 vaccines? Scientists and regulators chart a course amid uncertainty
Just over 2 years ago, the first COVID-19 vaccines arrived—and a roller coaster ride of hope and science began. It soon became clear that although the vaccines protected against severe disease, their ability to fend off infection was limited and faded fast. Meanwhile, SARS-CoV-2 began to evolve rapidly to elude immunity. By now, many people have had four or five vaccine doses, including an updated booster tailored to Omicron strains that was introduced last fall. Now, regulators and scientists are debating the near-term future. How often will we need booster doses and who should receive them? Should vaccines continu...
Source: Science of Aging Knowledge Environment - January 25, 2023 Category: Geriatrics Source Type: research

F.D.A. Outlines a Plan for Annual Covid Boosters
In advance of a scientific meeting on Thursday, officials proposed offering new shots to Americans each fall, a strategy long employed against the flu.
Source: NYT Health - January 23, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Omicron Variant Immune System Food and Drug Administration Influenza Disease Rates United States Source Type: news

The Incidence of Myocarditis Following an Influenza Vaccination: A Population-Based Observational Study
ConclusionsRegardless of the post-vaccination time and underlying baseline characteristics, the incidence risk of myocarditis is not significantly increased in the elderly following an influenza vaccination.
Source: Drugs and Aging - January 10, 2023 Category: Geriatrics Source Type: research

Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccinations targeting the spike protein (S) offer protective immunity against coronavirus disease 2019 (COVID-19). This immunity may further be shaped by cross-reactivity with common cold coronaviruses. Mutations arising in S that are associated with altered intrinsic virus properties and immune escape result in the continued circulation of SARS-CoV-2 variants. Potentially, vaccine updates will be required to protect against future variants of concern, as for influenza. To offer potent protection against future variants, these second-generati...
Source: Journal of Clinical Investigation - January 4, 2023 Category: Biomedical Science Authors: Muriel Aguilar-Bretones, Ron A.M. Fouchier, Marion P.G. Koopmans, Gijsbert P. van Nierop Source Type: research

IJERPH, Vol. 20, Pages 510: Lessons Learned from In-Person Conferences in the Times of COVID-19
In this study, we highlight the specific conditions and safety measures set in place at the conference. In addition to vaccination requirements, social distancing, and mask wearing, daily rapid testing was implemented for the duration of the conference. At the end of the 4-day meeting, none of the 166 delegates (and family members attending the conference) had tested antigen positive for SARS-CoV-2. Two delegates tested positive in the week after the conference; the timing of their positive test result suggests that they contracted the virus during their travels home or during postconference vacationing. We believe that th...
Source: International Journal of Environmental Research and Public Health - December 28, 2022 Category: Environmental Health Authors: Maryam Ehteshami Carlos Le ón Edgar Lucia Yunuen Delgado Ayala Michael Hagan Greg S. Martin Wilbur Lam Raymond F. Schinazi Tags: Article Source Type: research

The Case for Cautious COVID Optimism This Winter
At this time last year and two years ago, daily new infections and covid-related hospitalizations were already accelerating at a fast clip. BQ.1 and BQ.1.1, the latest Omicron subvariants, came to comprise the majority of cases during a relative lull in the pandemic. Combined with a Thanksgiving Holiday that saw the most travelers since the pandemic started, there has been a steady increase in covid metrics. However, there are many reasons to be optimistic. A combination of factors—a high level of population immunity, Omicron family antigenic drift, convergence of mutations that seem to have hit an evolutionary ceili...
Source: TIME: Health - December 13, 2022 Category: Consumer Health News Authors: Michael Daignault and Monica Gandhi Tags: Uncategorized COVID-19 freelance Source Type: news